ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first ... associate director of the division of pulmonology, allergy and critical care at the FDA's Center ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Following a regulatory setback last year, Satsuma Pharmaceuticals Inc. has won approval for its nasal powder migraine ...

The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without aura in adults ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray ... 15 and 30kg. Approved by the US Food and Drug Administration (FDA) in March 2025, the spray is now ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine ...

The FDA approved dihydroergotamine ... DHE is a migraine-specific acute medication first approved in 1946. It comes in several forms, including nasal sprays, injection, intravenous infusion ...